title: [General practitioners' perception of the impact of corticosteroid-induced adverse events].
abstract: BACKGROUND
  General practitioners' perception of the discomfort their patients experience because of corticosteroid-induced adverse events is unknown.
  
  
  METHODS
  An observational epidemiological study was conducted in September 2007. Eight hundred and sixty general practitioners belonging to the réseau Sentinelles were asked to complete an electronical questionnaire. The questionnaire aimed to assess their perception of discomfort induced by adverse events induced by a long-term (i.e.,>or=3 months) corticosteroid therapy among their patients. Results were compared with the declaration made by 115 long-term corticosteroid treated patients followed in an internal medicine department.
  
  
  RESULTS
  Two hundred and ninety-three general practitioners responded to the questionnaire (response rate: 34%). They were predominantly male (87%). Forty-eight percent of them reported 400 to 600 monthly visits. The mean length of corticosteroid therapy for patients was 44+/-38 months and the mean daily dosage was 15+/-14 mg. They suffered mainly from lupus erythematosus (33%) or giant cell arteritis (15%). The adverse events considered to be the most disturbing by patients were lipodystrophy (25%), followed by weight gain (18%) and neuropsychiatric complaints (16%). Physicians widely overestimated the discomfort caused by weight gain cited as the most disturbing adverse event by 59% of them and underestimated that induced by mood disorders cited as the most disturbing by only 3% of them.
  
  
  CONCLUSIONS
  The discomfort caused by corticosteroid-induced neuropsychiatric adverse events are underestimated by general practitioners.
authors.affiliation: Service de médecine interne horloge 2, hôpital Saint-Antoine, AP-HP, 184, rue du Faubourg-Saint-Antoine, 75012 Paris, France.
authors.forename: A
authors.initials: A
authors.lastname: Perdoncini-Roux
authors.forename: T
authors.initials: T
authors.lastname: Blanchon
authors.forename: T
authors.initials: T
authors.lastname: Hanslik
authors.forename: A
authors.initials: A
authors.lastname: Lasserre
authors.forename: C
authors.initials: C
authors.lastname: Turbelin
authors.forename: Y
authors.initials: Y
authors.lastname: Dorleans
authors.forename: J
authors.initials: J
authors.lastname: Cabane
authors.forename: L
authors.initials: L
authors.lastname: Fardet
mesh_terms: D000305:Adrenal Cortex Hormones / Q000008:administration & dosage / Q000009:adverse effects*; D000328:Adult; D000368:Aged; D001008:Anxiety Disorders / Q000139:chemically induced; D001291:Attitude of Health Personnel; D003627:Data Interpretation, Statistical; D003863:Depression / Q000139:chemically induced; D005194:Family Practice; D005260:Female; D013700:Giant Cell Arteritis / Q000188:drug therapy; D006801:Humans; D008060:Lipodystrophy / Q000139:chemically induced; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D019964:Mood Disorders / Q000139:chemically induced; D010465:Perception; D011795:Surveys and Questionnaires; D013997:Time Factors; D015430:Weight Gain
chemical_list: D000305:Adrenal Cortex Hormones